Media headlines about Forward Pharma A/S (NASDAQ:FWP) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Forward Pharma A/S earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.6005004028837 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Forward Pharma A/S (NASDAQ:FWP) traded down 2.282% on Thursday, hitting $6.938. 104,141 shares of the stock traded hands. The stock has a 50-day moving average price of $13.38 and a 200 day moving average price of $19.22. The company has a market cap of $327.47 million, a price-to-earnings ratio of 0.356 and a beta of 1.65. Forward Pharma A/S has a 1-year low of $5.20 and a 1-year high of $33.00.
A number of brokerages recently issued reports on FWP. Jefferies Group LLC restated a “hold” rating and set a $6.00 price objective (up previously from $5.00) on shares of Forward Pharma A/S in a report on Wednesday, September 27th. BidaskClub cut shares of Forward Pharma A/S from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 21st. Finally, ValuEngine upgraded shares of Forward Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.00.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Forward Pharma A/S (FWP) Share Price” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/10/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-forward-pharma-as-fwp-share-price.html.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.